Poniard Pharmaceuticals Inc

Summary

Introduction

Poniard Pharmaceuticals, formerly known as NeoRx Corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapy products. The company's lead product candidate, Picoplatin, is currently in Phase III clinical development for small cell lung cancer and offers a huge opportunity for the company to achieve its first commercial success.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company's product pipeline includes single product, Picoplatin, a new generation cytotoxic platinum compound that provides a differentiated spectrum of activity and an improved safety profile. Picoplatin is being developed for small cell lung cancer (Phase III), colorectal cancer (Phase II), and prostate cancer (Phase II). The company does not have any significant ongoing revenue sources till date. On occasion, the company derives revenues from the sale or licensing of its patented technologies and from government grants. The company's total revenues decreased from $11.1 million in 2002 to absolute zero in 2006. For the fiscal 2006, the company did not recognize any revenues due to non-recognition of any royalties for licensed intellectual property as recognized in 2004 and 2005 from Boston Scientific.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content